Center Ventures

Center Ventures has evolved from a pharmaceutical manufacturer into one of Asia Pacific’s leading biotech venture capital firms and incubators. It has successfully invested in or incubated numerous biotech/pharma startups that have gone on to IPO or achieve significant milestones. The group maintains strong expertise in oral liquid pharmaceuticals while expanding into biologics, cell therapy, antibody-drug conjugates (ADCs), medical devices, probiotics/supplements through its investments. Its own developed diabetes drug candidate "CS02" reached Phase II clinical trials with US FDA/Taiwan TFDA approval for trial entry as of 2018. Recent years saw successful mergers/acquisitions such as Glac Biotech contributing significantly to revenue growth.